Streetbeat News

PODD

Insulet Corporation

https://www.insulet.com

Industry

Medical - Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Open

256.90

Mkt cap

19B

Volume

1.5M

High

275.52

P/E Ratio

45.58

52-wk high

275.52

Low

254.44

Div yield

N/A

52-wk low

152.04

Insulet (NASDAQ:PODD) has been analyzed by 7 analysts, showing a range of opinions. The average 12-month price target is $213.29, with a high of $250 and a low of $162, marking a 13.71% decrease in the average target. Analysts from firms like Baird, Morgan Stanley, Piper Sandler, JP Morgan, Leerink Partners, and Jefferies have adjusted their ratings and price targets. Insulet's financials show strong revenue growth and ROE, but a high debt-to-equity ratio and below-average net margin.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

Baird analyst Jeff Johnson upgraded Insulet (NASDAQ:PODD) from Neutral to Outperform and increased the price target from $180 to $238, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 10:15 am

Over the past quarter, Insulet (NASDAQ:PODD) received 8 analyst ratings, with 1 bullish, 5 somewhat bullish, and 2 indifferent. The average 12-month price target for Insulet is $212.25, with a high of $250.00 and a low of $162.00. This average has decreased by 20.63% from the previous average price target of $267.43. Analysts rate stocks based on company financials, meetings, and insider information, providing guidance to investors.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 1:00 pm

Morgan Stanley analyst Patrick Wood upgraded Insulet (NASDAQ:PODD) from Equal-Weight to Overweight and increased the price target from $185 to $234.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 12:27 pm

Medical device and diabetes care stocks are trading higher following the presentation of SELECT data by Novo Nordisk. Raymond James commented that the data presented did not contain major surprises and could be considered as 'modestly de-risking' for the sector.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:38 pm

U.S. stock futures indicate a lower open on Monday, influenced by Moody's downgrade of the U.S. sovereign rating outlook and anticipation of inflation data and Federal Reserve officials' speeches. Despite last week's gains, with the Nasdaq Composite and S&P 500 ending higher, the Russell 2000 faced selling pressure. Analysts express mixed sentiments, with some seeing resilience in the market and others predicting a tech bull market. Key companies like Plug Power and Walt Disney saw premarket movements, while Boeing rose on news of potential Chinese purchases of its 737 Max aircraft.

Portfolio Pulse from Shanthi Rexaline

November 13, 2023 | 12:15 pm

The U.S. stock market has seen a record rally in November, with the S&P 500 and Nasdaq 100 experiencing their longest sustained uptrend in two years. The rally was driven by a dovish Fed meeting and softer labor market data. The technology sector outperformed all other sectors within the S&P 500 index, with the Technology Select Sector SPDR Fund (NYSE:XLK) surging by 6.5% month-to-date. The top performing S&P 500 stocks month-to-date include Expedia Group Inc. (NASDAQ:EXPE), Generac Holdings Inc. (NYSE:GNRC), and Insulet Corp. (NASDAQ:PODD).

Portfolio Pulse from Piero Cingari

November 07, 2023 | 6:13 pm

Barron's weekend stock picks include Chevron, Apple, Disney, and Insulet. Chevron's stock is down 17% in 2023, but its long-term potential and attractive valuation may provide a 4.5% dividend yield. Apple's recent quarterly report revealed a lack of growth with declining revenue. Disney faces a renewed activist campaign led by Trian Fund Management. KeyBanc Capital Markets downgraded Bill Holdings after a disappointing Q1 outlook. Insulet saw its stock rise by 15% as the company raised its revenue outlook.

Portfolio Pulse from Justin Chan

November 04, 2023 | 8:37 pm

Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on Insulet (NASDAQ:PODD), but lowered the price target from $325 to $250.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:32 pm

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, beating the consensus of $414.383 million. The company also reported an adjusted EPS of $0.71, beating the consensus of $0.40. Insulet raised its FY23 revenue growth forecast to 26%-27% and expects total Omnipod growth between 29% and 30%. The company also received FDA clearance for the Omnipod 5 app on Apple iOS and plans to integrate Omnipod 5 with the Dexcom G7 by early 2024.

Portfolio Pulse from Vandana Singh

November 03, 2023 | 1:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.